These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26759009)

  • 1. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
    Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
    Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bacillus Calmette-Guerin and interferon-alpha-2B on human bladder cancer in vitro.
    Zhang Y; Khoo HE; Esuvaranathan K
    Int J Cancer; 1997 May; 71(5):851-7. PubMed ID: 9180156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
    Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
    Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
    Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
    Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth.
    Higuchi T; Shimizu M; Owaki A; Takahashi M; Shinya E; Nishimura T; Takahashi H
    Cancer Immunol Immunother; 2009 Aug; 58(8):1245-55. PubMed ID: 19139883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
    Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
    Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
    Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
    APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
    Begnini KR; Buss JH; Collares T; Seixas FK
    Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
    Luo Y; Han R; Evanoff DP; Chen X
    Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
    J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
    Kresowik TP; Griffith TS
    Immunotherapy; 2009 Mar; 1(2):281-8. PubMed ID: 20046960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.
    Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
    J Urol; 1984 Jan; 131(1):139-42. PubMed ID: 6418894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
    Wu C; Zhou X; Miao C; Zhang J; Tang Q; Chang X; Ni H
    Cell Physiol Biochem; 2017; 41(4):1298-1312. PubMed ID: 28278504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo.
    Jinesh GG; Lee EK; Tran J; Kamat AM
    Urol Oncol; 2013 Nov; 31(8):1676-1682. PubMed ID: 22717623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
    Simons MP; Nauseef WM; Griffith TS
    Immunol Res; 2007; 39(1-3):79-93. PubMed ID: 17917057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
    Kamat AM; Tharakan ST; Sung B; Aggarwal BB
    Cancer Res; 2009 Dec; 69(23):8958-66. PubMed ID: 19903839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study.
    Özcan Y; Çağlar F; Celik S; Demir AB; Erçetin AP; Altun Z; Aktas S
    Urol Oncol; 2020 May; 38(5):476-487. PubMed ID: 32192892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.
    Gomes-Giacoia E; Miyake M; Goodison S; Sriharan A; Zhang G; You L; Egan JO; Rhode PR; Parker AS; Chai KX; Wong HC; Rosser CJ
    PLoS One; 2014; 9(6):e96705. PubMed ID: 24896845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.